PI: Sylvan Baca MD PhD
Sylvan Baca is an Assistant Professor of Medicine at Harvard Medical School, a medical oncologist at the Dana-Farber Cancer Institute, and an Associate Member of the Broad Institute. Raised in Albuquerque, NM, Dr. Baca received his undergraduate degree from Stanford University and his MD and PhD from Harvard Medical School. He trained in Internal Medicine at Brigham and Women's Hospital and completed his fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Baca received his post-doctoral training in cancer epigenetics with Dr. Matthew Freedman at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. He is on faculty at the Dana-Farber Cancer Institute as a Physician and Investigator. In addition to caring for patients, he conducts research at the interface of computational biology and epigenomics to find better ways to treat cancer.
Baca Lab mentees
Gunsagar Gulati MD PhD: Methods development and translational applications of cell-free epigenomics
Shahab Sotudian PhD: Machine learning classifiers of cancer based on cell-free DNA fragmentation
Miklós Dióssy PhD: Detecting prostate cancer phenotypes from circulating cell-free epigenomic data
David Osei-Hwedieh MD PhD: Circulating cell-free epigenomics of bone cancers
Karl Semaan MD: Circulating biomarkers for treatment selection in kidney cancer
Paulo Da Silva Cordeiro (PhD student): Computational methods development for fragmentomics
Medha Pandey PhD: cfDNA fragmentomics methods development and benchmarking
Chris Dall MD: Epigenetic correlates of resistance to antibody-drug conjugates
Alexis Yang (MEng student): Machine learning approaches to predict impact of non-coding variants in cancer
Ze Zhang PhD: Cell-type deconvolution from cell-free epigenomic data
Garyoung Lee PhD: In vivo readouts of transcription factor activity from patient plasma
Razane El Hajj Chehade MD: Minimal residual disease in kidney cancer
Shahab Sotudian PhD: Machine learning classifiers of cancer based on cell-free DNA fragmentation
Miklós Dióssy PhD: Detecting prostate cancer phenotypes from circulating cell-free epigenomic data
David Osei-Hwedieh MD PhD: Circulating cell-free epigenomics of bone cancers
Karl Semaan MD: Circulating biomarkers for treatment selection in kidney cancer
Paulo Da Silva Cordeiro (PhD student): Computational methods development for fragmentomics
Medha Pandey PhD: cfDNA fragmentomics methods development and benchmarking
Chris Dall MD: Epigenetic correlates of resistance to antibody-drug conjugates
Alexis Yang (MEng student): Machine learning approaches to predict impact of non-coding variants in cancer
Ze Zhang PhD: Cell-type deconvolution from cell-free epigenomic data
Garyoung Lee PhD: In vivo readouts of transcription factor activity from patient plasma
Razane El Hajj Chehade MD: Minimal residual disease in kidney cancer
Lab Alumni
Ziwei Zhang MS (currently a PhD student at Harvard School of Public Health)
Soumya Zacharia MS (currently a software engineer at Beebolt)
Jesslyn Goh MS (currently a software developer at InterSystems)
Talal El Zarif MD (currently an Internal Medicine resident at Yale)
Brad Fortunato MS (currently a bioinformatics software developer at BIDMC)
Soumya Zacharia MS (currently a software engineer at Beebolt)
Jesslyn Goh MS (currently a software developer at InterSystems)
Talal El Zarif MD (currently an Internal Medicine resident at Yale)
Brad Fortunato MS (currently a bioinformatics software developer at BIDMC)